Details of Disease

General Information of Disease (ID: DIS15W6U)

• Disease Name: Atrial fibrillation
• Synonyms: A-fib; atrial fibrillation; AFib; AF; atrial fibrillation (disease)
• Disease Class: BC81: Supraventricular tachyarrhythmia
• Definition: A disorder characterized by an electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregular ventricular response. (CDISC)
• Disease Hierarchy:
  DIS1W8PP: Tachyarrhythmias
  DIS15W6U: Atrial fibrillation
• ICD Code:
  ICD-11: ICD-11: BC81.3
  ICD-10: ICD-10: I48
  Expand ICD-11: 'BC81.3
  Expand ICD-10: 'I48
  Expand ICD-9: 272427.31
• Disease Identifiers:
  MONDO ID: MONDO_0004981
  MESH ID: D001281
  UMLS CUI: C0004238
  MedGen ID: 445
  HPO ID: HP:0005110
  SNOMED CT ID: 49436004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acocantherin	DM7JT24	Approved	Small molecular drug	[1]
Ajmaline	DMDJW5K	Approved	Small molecular drug	[2]
Digoxin	DMQCTIH	Approved	Small molecular drug	[3]
Diltiazem	DMAI7ZV	Approved	Small molecular drug	[4]
Dipyridamole	DMXY30O	Approved	Small molecular drug	[5]
Dronedarone	DMA8FS5	Approved	Small molecular drug	[6]
DU-176b	DMCIJBH	Approved	Small molecular drug	[7]
Flecainide	DMSQDLE	Approved	Small molecular drug	[8]
Ha-1a	DM3EVLE	Approved	NA	[2]
Ibutilide	DMKXY2R	Approved	Small molecular drug	[9]
Propranolol	DM79NTF	Approved	Small molecular drug	[10]
Verapamil	DMA7PEW	Approved	Small molecular drug	[11]
Warfarin	DMJYCVW	Approved	Small molecular drug	[12]

This Disease is Treated as An Indication in 20 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Azimilide	DMUIBV8	Phase 3	Small molecular drug	[13]
Vernakalant	DMOQ81Y	Phase 3	Small molecular drug	[14]
Vernakalant IV	DME0I5C	Phase 3	NA	[15]
BUCINDOLOL	DMV52CP	Phase 2/3	Small molecular drug	[15]
Abelacimab	DM09YTN	Phase 2	Monoclonal antibody	[16]
ATI-2042	DMWP59B	Phase 2	Small molecular drug	[17]
AZD-2927	DM6AI9N	Phase 2	Small molecular drug	[18]
AZD-7009	DMIBXK0	Phase 2	Small molecular drug	[19]
BMS-914392	DMX1IOC	Phase 2	NA	[20]
BMS-919373	DMN28WK	Phase 2	NA	[21]
Capadenoson	DMYWO62	Phase 2	Small molecular drug	[22]
Danegaptide	DM2U45Q	Phase 2	Small molecular drug	[23]
DTI-0009	DMV84OK	Phase 2	NA	[24]
HBI-3000	DM74ZKN	Phase 2	NA	[25]
Piboserod	DM3ZEYL	Phase 2	Small molecular drug	[26]
TB-402	DM4I6XK	Phase 2	Antibody	[27]
AP-30663	DMJLMEF	Phase 1/2	NA	[25]
OPC 108459	DM8PSSR	Phase 1	NA	[28]
XEN-D0101	DMU0V45	Phase 1	NA	[29]
XEN-D0103	DMR0U4V	Phase 1	NA	[30]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Tecadenoson	DM9T6MS	Discontinued in Phase 3	Small molecular drug	[31]
NK-1001	DMZMQDN	Discontinued in Phase 2	Small molecular drug	[32]
NTC-801	DM1QZKS	Discontinued in Phase 1	NA	[33]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
T-226296	DMJ6P9U	Preclinical	Small molecular drug	[8]

This Disease is Treated as An Indication in 10 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DPO-1	DMHCZP0	Investigative	Small molecular drug	[34]
F-16915	DM5ZC6K	Investigative	NA	[35]
NIP-142	DMV53PH	Investigative	Small molecular drug	[36]
NIP-151	DMVK9ZK	Investigative	NA	[35]
NK-1005	DMT06SR	Investigative	NA	[35]
NK-1007	DMCDU7O	Investigative	NA	[35]
NS-11757	DM98VMZ	Investigative	Small molecular drug	[37]
RS-100302	DM63NGW	Investigative	Small molecular drug	[8]
S-9947	DMHB6UY	Investigative	Small molecular drug	[38]
XEN-D0104	DM1EHG5	Investigative	NA	[34]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 164 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCC9	TTEF5MJ	Limited	Biomarker	[39]
CYP2C19	TTZ58XG	Limited	Genetic Variation	[40]
GATA4	TT1VDN2	Limited	Biomarker	[41]
GJA1	TT4F7SL	Limited	Biomarker	[42]
HCN4	TTQP04A	Limited	Biomarker	[43]
KCNJ5	TTEO25X	Limited	Biomarker	[44]
PCSK9	TTNIZ2B	Limited	Altered Expression	[45]
PLN	TTMCVJF	Limited	Altered Expression	[46]
PSMB7	TT49BVC	Limited	Biomarker	[47]
XPO1	TTCJUR4	Limited	Biomarker	[47]
CGA	TTFC29G	moderate	Biomarker	[41]
ERBB4	TTWALCO	moderate	Biomarker	[48]
HSPG2	TT5UM29	moderate	Biomarker	[41]
KCND3	TTPLQO0	moderate	Genetic Variation	[47]
NR3C1	TTOZRK6	moderate	Biomarker	[41]
SGCA	TTS9Q5V	moderate	Biomarker	[41]
SIRT1	TTUF2HO	moderate	Biomarker	[49]
SMAD7	TT0J32Z	moderate	Altered Expression	[50]
SOX5	TTXHSZK	moderate	Genetic Variation	[41]
TNFSF12	TTBTDM1	moderate	Genetic Variation	[41]
ABCB4	TTJUXV6	Strong	Genetic Variation	[51]
ACVR1B	TTPKHTZ	Strong	Biomarker	[52]
ADAMTS13	TTUREBK	Strong	Altered Expression	[53]
ADCYAP1R1	TT5OREU	Strong	Biomarker	[54]
ADRA2C	TT2NUT5	Strong	Genetic Variation	[55]
AMACR	TTLN1AP	Strong	Biomarker	[56]
APLN	TT87D3J	Strong	Altered Expression	[57]
APLNR	TTJ8E43	Strong	Biomarker	[57]
ARAF	TT5TURO	Strong	Genetic Variation	[58]
ATP7B	TTOPO51	Strong	Biomarker	[59]
ATXN3	TT6A17J	Strong	Biomarker	[60]
CACNA1C	TTZIFHC	Strong	Altered Expression	[61]
CAD	TT2YT1K	Strong	Genetic Variation	[62]
CALCR	TTLWS2O	Strong	Biomarker	[63]
CAPN2	TTG5QB7	Strong	Biomarker	[64]
CDK6	TTO0FDJ	Strong	Genetic Variation	[47]
CDKN1A	TT9GUW0	Strong	Genetic Variation	[47]
CES1	TTMF541	Strong	Genetic Variation	[65]
CETP	TTFQAYR	Strong	Genetic Variation	[66]
CHAT	TTKYFSB	Strong	Altered Expression	[67]
CHRM2	TTYEG6Q	Strong	Biomarker	[68]
CNTN2	TT2Z1WB	Strong	Genetic Variation	[69]
CPB1	TT4UJX5	Strong	Biomarker	[70]
CPM	TTVOH2M	Strong	Biomarker	[71]
CTSC	TT4H0V2	Strong	Biomarker	[72]
CYP11B2	TT9MNE2	Strong	Genetic Variation	[73]
CYP2C9	TTR40YJ	Strong	Biomarker	[74]
CYP2J2	TTNE1C7	Strong	Biomarker	[75]
CYP3A4	TTWP7HQ	Strong	Biomarker	[76]
EDN1	TTJR60Z	Strong	Altered Expression	[77]
EDN2	TTMR0OP	Strong	Genetic Variation	[78]
ENPEP	TT9PBIL	Strong	Genetic Variation	[79]
EPHA3	TTHS2LR	Strong	Biomarker	[47]
EPHX2	TT7WVHI	Strong	Genetic Variation	[80]
ESR2	TTOM3J0	Strong	Genetic Variation	[47]
F3	TT38MDJ	Strong	Biomarker	[81]
F7	TTF0EGX	Strong	Genetic Variation	[82]
FABP3	TT3TGLR	Strong	Altered Expression	[83]
FADS2	TTT2VDU	Strong	Genetic Variation	[84]
FAF1	TTSKL3G	Strong	Genetic Variation	[85]
FANCF	TTNZKFJ	Strong	Biomarker	[86]
FKBP1A	TTMW94E	Strong	Biomarker	[87]
FTO	TTFW3BT	Strong	Genetic Variation	[84]
G3BP1	TTG0R8Z	Strong	Altered Expression	[88]
GAP43	TTSGLN5	Strong	Altered Expression	[89]
GDF15	TT4MXVG	Strong	Biomarker	[90]
GGCX	TT76OLR	Strong	Genetic Variation	[91]
GJA4	TTQO1VY	Strong	Genetic Variation	[92]
GJC1	TTEP7OC	Strong	Biomarker	[93]
GLA	TTIS03D	Strong	Biomarker	[94]
GNRHR	TT8R70G	Strong	Biomarker	[95]
GRK5	TTTCXO0	Strong	Genetic Variation	[96]
HBEGF	TT15SL0	Strong	Genetic Variation	[97]
HCN2	TT9EUT4	Strong	Altered Expression	[98]
HDAC5	TTUELN5	Strong	Biomarker	[99]
HRC	TTR4FKD	Strong	Genetic Variation	[100]
HSD11B1	TTN7BL9	Strong	Genetic Variation	[101]
HSPA8	TTMQL3K	Strong	Biomarker	[102]
HTR4	TT07C3Y	Strong	Biomarker	[103]
IDE	TT2EDHU	Strong	Biomarker	[104]
IFNGR2	TT13TL0	Strong	Genetic Variation	[105]
IGF1R	TTQFBMY	Strong	Biomarker	[47]
INPP5D	TTTP2Z1	Strong	Biomarker	[106]
KAT2B	TTVK7SB	Strong	Genetic Variation	[71]
KCNA5	TTW0CMT	Strong	Genetic Variation	[107]
KCNB1	TT5OEKU	Strong	Genetic Variation	[108]
KCNH2	TTQ6VDM	Strong	Genetic Variation	[109]
KCNJ11	TT329V4	Strong	Genetic Variation	[110]
KCNJ2	TTH7UO3	Strong	Genetic Variation	[111]
KCNJ3	TTGM19J	Strong	Biomarker	[44]
KCNK3	TTGR91N	Strong	Biomarker	[112]
KCNK9	TTL4FMB	Strong	Biomarker	[113]
KCNN2	TT2T5M0	Strong	Genetic Variation	[47]
KCNQ1	TT846HF	Strong	Genetic Variation	[114]
KCNQ5	TTWVL5Q	Strong	Genetic Variation	[115]
KDM1B	TT8VP2T	Strong	Genetic Variation	[47]
LCAT	TTGZ91P	Strong	Altered Expression	[116]
LIMK1	TTWL9TY	Strong	Altered Expression	[117]
LIPE	TTLUQ8E	Strong	Altered Expression	[118]
LPA	TTU9LGY	Strong	Genetic Variation	[119]
LY96	TT8S9AV	Strong	Biomarker	[120]
MANF	TT56RYE	Strong	Biomarker	[121]
MAPK9	TT3IVG2	Strong	Biomarker	[122]
MAPT	TTS87KH	Strong	Genetic Variation	[47]
MSR1	TT2TDH9	Strong	Biomarker	[123]
NNT	TTKIH76	Strong	Biomarker	[124]
NOS3	TTCM4B3	Strong	Genetic Variation	[125]
NPPB	TTY63XT	Strong	Biomarker	[126]
NPPC	TTRK0B9	Strong	Altered Expression	[127]
NPR1	TTM9IYA	Strong	Altered Expression	[128]
NPY4R	TTW4N16	Strong	Posttranslational Modification	[129]
NR3C2	TT26PHO	Strong	Genetic Variation	[130]
OAT	TTTSCQ2	Strong	Biomarker	[131]
P2RY12	TTZ1DT0	Strong	Biomarker	[132]
PAK2	TT279WO	Strong	Genetic Variation	[47]
PEPD	TTLZXI0	Strong	Altered Expression	[133]
PLA2G7	TTDNFMT	Strong	Biomarker	[134]
PLCG1	TT6T4JI	Strong	Genetic Variation	[84]
PPOX	TTNFMS9	Strong	Biomarker	[135]
PSMB10	TTPNACM	Strong	Altered Expression	[136]
PSMB8	TTEAD9J	Strong	Altered Expression	[137]
PTK2	TTON5IT	Strong	Genetic Variation	[47]
RAPGEF3	TTOE7I0	Strong	Biomarker	[138]
RGS6	TTJ96M8	Strong	Biomarker	[139]
SCN2A	TTLJTUF	Strong	Biomarker	[140]
SCN5A	TTZOVE0	Strong	Genetic Variation	[141]
SELE	TT1PL7M	Strong	Altered Expression	[142]
SIGMAR1	TT5TPI6	Strong	Biomarker	[143]
SIK3	TTW6L4V	Strong	Genetic Variation	[84]
SIRPA	TTBRJS9	Strong	Biomarker	[144]
SLC33A1	TTL69WB	Strong	Genetic Variation	[145]
SLC52A2	TT6TKEN	Strong	Biomarker	[146]
SLC5A2	TTF8JAT	Strong	Genetic Variation	[147]
SLCO1B3	TTU86P0	Strong	Genetic Variation	[148]
SMAD3	TTHQZV7	Strong	Biomarker	[149]
SPRY1	TT0PSN6	Strong	Altered Expression	[150]
STAR	TTEI40H	Strong	Genetic Variation	[151]
TACR3	TTBPGLU	Strong	Biomarker	[152]
TBL1X	TTAL6S1	Strong	Genetic Variation	[153]
TCF7L2	TT80QAL	Strong	Genetic Variation	[84]
TFPI	TT068JH	Strong	Biomarker	[154]
TH	TTUHP71	Strong	Altered Expression	[67]
THRB	TTGER3L	Strong	Genetic Variation	[47]
TICAM1	TT2GQT6	Strong	Altered Expression	[155]
TNNI3	TTNLDK6	Strong	Biomarker	[90]
TRPC1	TTA76X0	Strong	Biomarker	[77]
TRPC3	TTNVC34	Strong	Altered Expression	[49]
TRPM6	TTV76RD	Strong	Altered Expression	[156]
TRPM7	TTFPVZO	Strong	Biomarker	[157]
TTR	TTPOYU7	Strong	Biomarker	[158]
TUSC2	TTJ8O14	Strong	Biomarker	[159]
UBC	TTBP3XA	Strong	Biomarker	[160]
UCP1	TTI12YJ	Strong	Altered Expression	[161]
UTS2	TTERU0T	Strong	Genetic Variation	[162]
VKORC1	TTEUC8H	Strong	Genetic Variation	[163]
VWF	TT3SZBT	Strong	Biomarker	[164]
WWP1	TTBWMKT	Strong	Biomarker	[165]
ZAP70	TTUMHT8	Strong	Biomarker	[166]
ACE2	TTUI5H7	Definitive	Genetic Variation	[167]
ADRB1	TTR6W5O	Definitive	Genetic Variation	[168]
ANGPT2	TTKLQTJ	Definitive	Genetic Variation	[169]
DPP4	TTDIGC1	Definitive	Biomarker	[170]
F2R	TTL935N	Definitive	Biomarker	[146]
SELP	TTE5VG0	Definitive	Biomarker	[171]

This Disease Is Related to 14 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCB6	DTF9Y2V	Limited	Biomarker	[172]
ATP2B1	DTJWQ1L	Strong	Genetic Variation	[84]
CACNB2	DTBZWL4	Strong	Genetic Variation	[173]
KCNK2	DTENHUP	Strong	Altered Expression	[174]
SLC22A25	DTP4ZNI	Strong	Genetic Variation	[175]
SLC24A3	DTO18LP	Strong	Altered Expression	[176]
SLC25A20	DTQOUM4	Strong	Altered Expression	[177]
SLC25A26	DT8HR5O	Strong	Genetic Variation	[47]
SLC27A6	DTG4CWJ	Strong	Genetic Variation	[47]
SLC28A1	DT0EQPW	Strong	Genetic Variation	[178]
SLC30A1	DT1BO38	Strong	Altered Expression	[179]
SLC30A3	DTKMECW	Strong	Genetic Variation	[84]
SLC39A8	DTLPQGT	Strong	Genetic Variation	[84]
SLC9B1	DTR462N	Strong	Genetic Variation	[47]

This Disease Is Related to 8 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACSS2	DEE76VW	Strong	Biomarker	[180]
ALDH1A2	DEKN1H4	Strong	Genetic Variation	[84]
CES2	DETHCPD	Strong	Biomarker	[181]
CYP4F2	DE3GT9C	Strong	Genetic Variation	[182]
FADS1	DE05S8C	Strong	Genetic Variation	[84]
MSRA	DEU2ZBY	Strong	Altered Expression	[183]
SULT2A1	DE0P6LK	Strong	Biomarker	[166]
THOP1	DE95LJC	Strong	Genetic Variation	[184]

This Disease Is Related to 294 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
C1orf185	OT32C5NW	Limited	Biomarker	[47]
DECR1	OTCDIR6X	Limited	Altered Expression	[185]
GOPC	OTRBGH71	Limited	Biomarker	[47]
KCNE2	OTUO214Y	Limited	Genetic Variation	[111]
KCNE3	OTKWKR91	Limited	Biomarker	[186]
KCNE5	OTF4JYGZ	Limited	Genetic Variation	[187]
KCNJ8	OTZ8G8FE	Limited	Biomarker	[188]
MBD5	OTFHT4MO	Limited	Biomarker	[47]
MYL4	OTURFCSE	Limited	Genetic Variation	[42]
NACA	OTLP1KR3	Limited	Biomarker	[47]
NEURL1	OT2C4P70	Limited	Genetic Variation	[189]
NOC2L	OTNT7R33	Limited	Biomarker	[190]
PCLAF	OTMVIOUU	Limited	Biomarker	[191]
SCN1B	OTGD78J3	Limited	Genetic Variation	[192]
SCN2B	OTFAHJ38	Limited	Genetic Variation	[192]
SCN3B	OTNTQT9O	Limited	Genetic Variation	[192]
SCN4B	OT3JSUWO	Limited	Genetic Variation	[192]
SLN	OTERIU75	Limited	Altered Expression	[193]
SNRNP27	OTNWI55E	Limited	Biomarker	[47]
TCFL5	OTJL4348	Limited	Biomarker	[194]
TTN	OT0LZ058	Limited	Genetic Variation	[195]
AOPEP	OT0MMANL	moderate	Genetic Variation	[47]
ARNT2	OTAQD3YV	moderate	Biomarker	[41]
CALU	OTSYQN71	moderate	Biomarker	[41]
CAND2	OTOMOG3R	moderate	Genetic Variation	[196]
CASQ2	OT09MNQ8	moderate	Genetic Variation	[197]
CFL2	OTE2W0DH	moderate	Biomarker	[41]
DES	OTI09KBW	moderate	Biomarker	[198]
FGF5	OTQXGHBY	moderate	Biomarker	[41]
HAND2	OTCXYW4Y	moderate	Genetic Variation	[47]
IRF2BPL	OTV8MNT1	moderate	Biomarker	[41]
LRRC10	OT9V0ZBY	moderate	Biomarker	[41]
MYO1C	OT69L39Y	moderate	Biomarker	[41]
MYOT	OTCEW5XW	moderate	Biomarker	[41]
MYPN	OTHTOFDU	moderate	Biomarker	[41]
NEBL	OT2WH1NC	moderate	Genetic Variation	[97]
PHLDA1	OTFTWMIQ	moderate	Biomarker	[41]
PRRX1	OTTZK5G8	moderate	Genetic Variation	[47]
RBM20	OTOQZNKS	moderate	Genetic Variation	[47]
REEP1	OTEMVFX7	moderate	Biomarker	[41]
SORL1	OTQ8FFNS	moderate	Biomarker	[41]
SOX15	OTTB37I1	moderate	Biomarker	[41]
SYNE2	OTBUXGQ0	moderate	Genetic Variation	[47]
SYNPO2L	OTA7RKXZ	moderate	Biomarker	[47]
ABHD17C	OTB1MTOI	Strong	Genetic Variation	[41]
ACCS	OTHIHI9D	Strong	Biomarker	[180]
ACOT7	OT7C68YV	Strong	Biomarker	[199]
ACTBL2	OTD6B81U	Strong	Biomarker	[199]
ACTN2	OT9FOLD7	Strong	Genetic Variation	[200]
ADAM15	OTZ7VLTP	Strong	Altered Expression	[201]
AGBL4	OTOX2H61	Strong	Biomarker	[47]
AGFG2	OTXQZHCR	Strong	Biomarker	[202]
AGXT2	OTO6QUTM	Strong	Biomarker	[203]
AHSP	OTTHBSUS	Strong	Biomarker	[204]
AKAP6	OTN59BZS	Strong	Genetic Variation	[47]
ALPK1	OTBW6SGD	Strong	Genetic Variation	[41]
ANAPC10	OTM03SME	Strong	Biomarker	[205]
ANK2	OTWB4R1Y	Strong	Biomarker	[206]
ANXA4	OTUCRYXL	Strong	Genetic Variation	[207]
APBB3	OTNUTR0N	Strong	Biomarker	[123]
ARHGAP10	OT84ATF5	Strong	Biomarker	[47]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[208]
ARID3B	OTUP9MS4	Strong	Genetic Variation	[209]
ARIH1	OTO3XDR2	Strong	Biomarker	[210]
ARMH3	OT51CU4J	Strong	Genetic Variation	[47]
ASAH1	OT1DNGXL	Strong	Genetic Variation	[47]
ASAP1	OT4DLRYY	Strong	Biomarker	[159]
ASAP2	OTGEXULW	Strong	Biomarker	[159]
ATP2A3	OTFYDEES	Strong	Biomarker	[211]
ATP6AP2	OT0IABVV	Strong	Biomarker	[212]
ATXN1	OTQF0HNR	Strong	Genetic Variation	[47]
BAZ1B	OTD5KR2J	Strong	Genetic Variation	[84]
BEST3	OTMY8G20	Strong	Biomarker	[47]
BET1	OTGX2557	Strong	Biomarker	[213]
C1QL1	OTNQ0G3E	Strong	Biomarker	[70]
C1QTNF5	OTLKU5I2	Strong	Biomarker	[214]
C1QTNF9	OTLI3VA3	Strong	Altered Expression	[215]
CACNA2D4	OTVYNX7N	Strong	Genetic Variation	[173]
CAMK2D	OTJ5XLVU	Strong	Genetic Variation	[47]
CAP2	OTC1WFNO	Strong	Biomarker	[216]
CASP8AP2	OTTWT68S	Strong	Genetic Variation	[217]
CASZ1	OTWJ2OR8	Strong	Genetic Variation	[47]
CAV2	OT1FGRQX	Strong	Biomarker	[218]
CAV3	OTWSFDB4	Strong	Altered Expression	[219]
CCDC141	OTQ9HA3I	Strong	Genetic Variation	[220]
CCDC92	OT1YHLOR	Strong	Genetic Variation	[47]
CD2AP	OTC76KQM	Strong	Biomarker	[221]
CDK2AP1	OTNFOHDJ	Strong	Biomarker	[205]
CELSR2	OTON6JSZ	Strong	Genetic Variation	[84]
CEP68	OTZDM4J1	Strong	Genetic Variation	[47]
CEP85L	OTSHJFOT	Strong	Genetic Variation	[47]
CERT1	OTNUCNHX	Strong	Genetic Variation	[84]
CHAF1A	OTXSSY4H	Strong	Genetic Variation	[71]
CLIC2	OTDBURM4	Strong	Genetic Variation	[222]
CNTN5	OTWU5FLZ	Strong	Genetic Variation	[223]
COG5	OTZEG7K0	Strong	Genetic Variation	[47]
COL4A2	OTJK1LKN	Strong	Biomarker	[224]
COL9A1	OTWBR27Y	Strong	Biomarker	[225]
COL9A2	OT1ZBDBV	Strong	Biomarker	[225]
COL9A3	OTCUJOEK	Strong	Biomarker	[225]
CRAMP1	OT0X95YA	Strong	Genetic Variation	[41]
CREB5	OTJDUJPI	Strong	Genetic Variation	[47]
CRYGC	OTYSTQWI	Strong	Biomarker	[226]
CSAD	OT3I2G0A	Strong	Biomarker	[227]
CSH1	OT33HTRR	Strong	Biomarker	[228]
CSH2	OTW8JVAN	Strong	Biomarker	[228]
CTNNBL1	OT6KLHPA	Strong	Genetic Variation	[229]
CTRL	OTB6NA5O	Strong	Altered Expression	[137]
CUL4A	OTTBV70J	Strong	Biomarker	[47]
CUX2	OTDJTQAJ	Strong	Genetic Variation	[196]
CYTH1	OTYH9NRJ	Strong	Biomarker	[47]
DCBLD1	OTA702JK	Strong	Genetic Variation	[47]
DDT	OTF5HTYL	Strong	Altered Expression	[230]
DESI1	OTFNIW98	Strong	Biomarker	[231]
DGKB	OTTT9SZJ	Strong	Genetic Variation	[47]
DNAH10	OTABM2D1	Strong	Genetic Variation	[47]
DOC2A	OT5G9V94	Strong	Biomarker	[205]
DPF3	OTEWLMNB	Strong	Genetic Variation	[47]
DUSP2	OTH54FMR	Strong	Biomarker	[54]
EBPL	OT59J1GY	Strong	Biomarker	[232]
ECRG4	OTHZYUXX	Strong	Altered Expression	[233]
ECT2	OTQDUCT6	Strong	Genetic Variation	[234]
EFNA5	OTOH4DRR	Strong	Genetic Variation	[105]
EMD	OTR8ZANE	Strong	Genetic Variation	[235]
ENHO	OT91QASK	Strong	Biomarker	[236]
ERCC6	OT2QZKSF	Strong	Biomarker	[228]
ETV1	OT6PMJIK	Strong	Altered Expression	[237]
FANCC	OTTIDM3P	Strong	Altered Expression	[238]
FASTK	OTTHFZMP	Strong	Genetic Variation	[239]
FBRSL1	OT4BPXGG	Strong	Biomarker	[47]
FBXO32	OTUE978R	Strong	Genetic Variation	[47]
FGB	OT6RKLI9	Strong	Genetic Variation	[240]
FHL5	OT6C00Z1	Strong	Biomarker	[199]
FILIP1L	OTPY8IMS	Strong	Biomarker	[205]
FLOT2	OTZ0QR5L	Strong	Biomarker	[241]
FLVCR1	OT9XCFOC	Strong	Altered Expression	[242]
FOXK2	OTFXDZ3R	Strong	Genetic Variation	[243]
FRMD4B	OTVI6YFP	Strong	Biomarker	[47]
GATA5	OTO81B63	Strong	Genetic Variation	[244]
GATA6	OTO2BC0F	Strong	Genetic Variation	[245]
GCKR	OTSIWXGG	Strong	Genetic Variation	[84]
GDF7	OTNZY74B	Strong	Altered Expression	[246]
GGTLC1	OTWJKUHQ	Strong	Genetic Variation	[247]
GMCL1	OTRZHUFV	Strong	Genetic Variation	[41]
GNB3	OTA6HYBA	Strong	Genetic Variation	[248]
GNB4	OTC1GPHA	Strong	Genetic Variation	[47]
GOSR2	OTYHIYN2	Strong	Genetic Variation	[47]
GPD1L	OTVLWW9T	Strong	Genetic Variation	[249]
GREM2	OTE91EWT	Strong	Biomarker	[250]
GRHL1	OTZ4MNEW	Strong	Genetic Variation	[84]
GTF2I	OTUYL1TQ	Strong	Genetic Variation	[47]
GYPC	OTOEDR7O	Strong	Biomarker	[47]
HARS1	OTHOEOTS	Strong	Biomarker	[251]
HERC1	OT73FVYZ	Strong	Genetic Variation	[41]
HEY2	OTU4J3ZI	Strong	Genetic Variation	[252]
HGS	OTCYYCAC	Strong	Biomarker	[251]
HIP1R	OTIPKEJC	Strong	Biomarker	[47]
HOPX	OTBSR6C9	Strong	Biomarker	[253]
HSF2	OTXNJIJ9	Strong	Altered Expression	[254]
HSPA1L	OTC2V1K6	Strong	Genetic Variation	[255]
IL6R	OTCQL07Z	Strong	Altered Expression	[256]
INCENP	OT9HFRYK	Strong	Biomarker	[257]
INPPL1	OTCDAVBQ	Strong	Altered Expression	[106]
INSRR	OT3F75WA	Strong	Biomarker	[258]
ITGA2B	OT4Y17PY	Strong	Altered Expression	[259]
ITPK1	OTP4PGL6	Strong	Genetic Variation	[84]
JAML	OTOJHNEV	Strong	Biomarker	[260]
JPH2	OTL9YH7V	Strong	Biomarker	[237]
JTB	OT314JB6	Strong	Altered Expression	[261]
KCNAB2	OTH115IE	Strong	Genetic Variation	[262]
KCNE1	OTZNQUW9	Strong	Genetic Variation	[263]
KCNE4	OTNYW0OL	Strong	Biomarker	[264]
KCNIP1	OTGLGK1R	Strong	Genetic Variation	[265]
KCNIP2	OTY4BLOJ	Strong	Altered Expression	[98]
KCNK1	OTBXPTKX	Strong	Genetic Variation	[266]
KCNK13	OTMOT2KX	Strong	Altered Expression	[267]
KCNK17	OTG2NEZM	Strong	Genetic Variation	[268]
KCNK7	OTFJOWT4	Strong	Biomarker	[269]
KIF3C	OTTXKIWA	Strong	Genetic Variation	[47]
LHX3	OTQ5BAJ9	Strong	Biomarker	[47]
LIPC	OTZY5SC9	Strong	Genetic Variation	[84]
LRIG1	OTY5HZN5	Strong	Genetic Variation	[47]
LRMDA	OTIPNKTU	Strong	Genetic Variation	[47]
LYST	OTIUB1B3	Strong	Genetic Variation	[270]
MAML3	OTZFV53Z	Strong	Genetic Variation	[84]
MAP2K4	OTZPZX11	Strong	Altered Expression	[271]
MAP3K7CL	OT9J7RLC	Strong	Biomarker	[272]
MAP6	OTPUI00F	Strong	Biomarker	[273]
MEX3C	OT8AJG1I	Strong	Biomarker	[47]
MFAP4	OT5W64QY	Strong	Biomarker	[274]
MFRP	OTHY9ZA5	Strong	Biomarker	[214]
MINK1	OTKB0RA8	Strong	Genetic Variation	[275]
MLLT6	OTOC9OGX	Strong	Biomarker	[276]
MMP28	OTHQZXM1	Strong	Biomarker	[277]
MRPS30	OTDXIAGG	Strong	Biomarker	[159]
MTPAP	OT6HQ02S	Strong	Biomarker	[159]
MYH6	OT3YNCH1	Strong	Genetic Variation	[41]
MYO18B	OTGYY4NK	Strong	Genetic Variation	[47]
MYOCD	OTSJNHTH	Strong	Genetic Variation	[47]
MYOZ1	OT2XU9EU	Strong	Biomarker	[41]
MYZAP	OTAZCNBT	Strong	Genetic Variation	[41]
NANS	OTMQ2FUH	Strong	Biomarker	[278]
NAV2	OTGAOL01	Strong	Genetic Variation	[47]
NDUFS4	OTJKUYEE	Strong	Biomarker	[279]
NFATC3	OTYOORME	Strong	Altered Expression	[280]
NFATC4	OTTDCUAO	Strong	Altered Expression	[280]
NHS	OTKE8QAT	Strong	Biomarker	[281]
NIBAN2	OTVDQSPI	Strong	Biomarker	[282]
NKX2-6	OTPPKGTE	Strong	Biomarker	[283]
NLRP6	OTEREN4W	Strong	Genetic Variation	[284]
NPPA	OTMQNTNX	Strong	Biomarker	[254]
NPTXR	OTQJEOIH	Strong	Biomarker	[169]
NUCKS1	OTL4VJC5	Strong	Genetic Variation	[47]
NUP155	OTIIAH4E	Strong	Genetic Variation	[202]
PAPOLA	OTPHD65D	Strong	Biomarker	[159]
PDAP1	OTJSWMOD	Strong	Biomarker	[159]
PDK4	OTCMHMBZ	Strong	Altered Expression	[177]
PDZK1IP1	OTWA6M5K	Strong	Biomarker	[199]
PELI1	OTMLBCLC	Strong	Biomarker	[285]
PEX26	OT5AM0BM	Strong	Genetic Variation	[47]
PHB2	OTCAX3AW	Strong	Biomarker	[286]
PHLDB2	OTDKMB2G	Strong	Biomarker	[47]
PKD2	OTIXBU8H	Strong	Genetic Variation	[287]
PKD2L2	OTJH1UNR	Strong	Genetic Variation	[207]
PKP2	OTJOVF68	Strong	Genetic Variation	[47]
PLA2G15	OT6VJTPA	Strong	Biomarker	[180]
PLEC	OTU4XDEG	Strong	Genetic Variation	[288]
PLIN2	OTRXJ9UN	Strong	Biomarker	[118]
POLK	OTKZ38JH	Strong	Genetic Variation	[84]
POTEM	OT7L2HGH	Strong	Biomarker	[199]
PPA1	OTHZK1QB	Strong	Posttranslational Modification	[129]
PPBP	OT1FHGQS	Strong	Biomarker	[289]
PPFIA4	OTWXG0DO	Strong	Genetic Variation	[47]
PPM1K	OTNZ4N4E	Strong	Genetic Variation	[209]
PPP1R3A	OTJL9VYP	Strong	Biomarker	[129]
PPP2R3A	OTSK5GFC	Strong	Biomarker	[47]
PRKAG2	OTHTAM54	Strong	Genetic Variation	[290]
PRKRA	OTUTVZZU	Strong	Genetic Variation	[291]
PRM3	OT6574BF	Strong	Biomarker	[233]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[292]
PRSS21	OT8ZYC7G	Strong	Genetic Variation	[293]
PSMD4	OTH1VZTM	Strong	Genetic Variation	[105]
PSMG1	OTZ5I6UM	Strong	Biomarker	[54]
RAPGEF5	OT53VS75	Strong	Biomarker	[294]
RBBP6	OTTVG4HU	Strong	Genetic Variation	[291]
REEP3	OTM7YVIE	Strong	Genetic Variation	[47]
RETN	OTW5Z1NH	Strong	Biomarker	[295]
RGPD2	OTMUZ0HX	Strong	Biomarker	[202]
RLN2	OTY3OG71	Strong	Biomarker	[296]
RMC1	OT7K8MTJ	Strong	Altered Expression	[90]
RNASE1	OTKZ7CO9	Strong	Biomarker	[297]
RPE	OT0XT3JU	Strong	Biomarker	[298]
RPL3L	OTTNH7PK	Strong	Genetic Variation	[47]
RPS2	OTSMTZVB	Strong	Genetic Variation	[47]
RPS27A	OTIIGGZ2	Strong	Biomarker	[160]
RRAS	OTBBF28C	Strong	Genetic Variation	[299]
RYR2	OT0PF19E	Strong	Genetic Variation	[46]
SCMH1	OTPMWOM9	Strong	Genetic Variation	[47]
SEMA5B	OTUVSKK0	Strong	Genetic Variation	[84]
SESN3	OTJRY1Y5	Strong	Biomarker	[300]
SH2B1	OTJZO2CI	Strong	Biomarker	[301]
SH3PXD2A	OTYRQJIH	Strong	Genetic Variation	[85]
SHC1	OT1J5IRN	Strong	Altered Expression	[302]
SHOX2	OTLCZZJW	Strong	Genetic Variation	[303]
SIL1	OTDI85I5	Strong	Biomarker	[286]
SLC35F1	OTRXHR2P	Strong	Genetic Variation	[47]
SLC35G1	OTKZUA8O	Strong	Biomarker	[231]
SLIT3	OTU8MKEU	Strong	Biomarker	[47]
SMIM10L2B	OT04IG2N	Strong	Biomarker	[304]
SNTA1	OTUICTGZ	Strong	Genetic Variation	[249]
SNX17	OT2I652M	Strong	Biomarker	[107]
SPATC1L	OTED6WB8	Strong	Genetic Variation	[175]
SPATS2L	OTFO07H8	Strong	Biomarker	[47]
SRA1	OTYOGMTG	Strong	Biomarker	[123]
SRSF5	OTC5WP98	Strong	Biomarker	[251]
SSPN	OTYG2SL7	Strong	Genetic Variation	[47]
ST13	OTNML6UP	Strong	Biomarker	[253]
STIP1	OT7TXLOX	Strong	Biomarker	[253]
SUGP1	OT7W0EB8	Strong	Genetic Variation	[84]
SUN1	OTIU8V4U	Strong	Genetic Variation	[47]
TAT	OT2CJ91O	Strong	Biomarker	[305]
TBX5	OT70PISV	Strong	Biomarker	[306]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[208]
TIMP4	OT8A68SW	Strong	Altered Expression	[307]
TRIM69	OTTEGTRD	Strong	Altered Expression	[155]
TRIM72	OTFAFXPC	Strong	Altered Expression	[308]
TSPAN31	OT8WQ83R	Strong	Biomarker	[278]
TSPAN33	OTH6C0WU	Strong	Genetic Variation	[309]
TSPAN8	OT1F68WQ	Strong	Genetic Variation	[110]
CREM	OTJIJ5AL	Definitive	Altered Expression	[285]
FSD1	OT8P6PT3	Definitive	Altered Expression	[310]
FSD1L	OTBQ48RF	Definitive	Altered Expression	[310]
SMAD2	OTC6VB4K	Definitive	Biomarker	[215]
TIMP2	OT8S1RRP	Definitive	Biomarker	[311]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4826).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Digoxin FDA Label
• [4] Diltiazem FDA Label
• [5] Dipyridamole FDA Label
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7465).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7575).
• [8] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7200).
• [10] Propranolol FDA Label
• [11] Verapamil FDA Label
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6853).
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2588).
• [14] Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] ClinicalTrials.gov (NCT04755283) A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA). U.S.National Institutes of Health.
• [17] ClinicalTrials.gov (NCT00389792) Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers. U.S. National Institutes of Health.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704).
• [19] ClinicalTrials.gov (NCT00255281) Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT01356914) Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT02156076) A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT00568945) Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT01977755) Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT00040001) Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation. U.S. National Institutes of Health.
• [25] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 225).
• [27] ClinicalTrials.gov (NCT00793234) Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery. U.S. National Institutes of Health.
• [28] ClinicalTrials.gov (NCT01483183) Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation. U.S. National Institutes of Health.
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018084)
• [30] ClinicalTrials.gov (NCT02390258) Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103. U.S. National Institutes of Health.
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5592).
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033456)
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023917)
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
• [35] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [36] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2408).
• [37] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944).
• [38] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2562).
• [39] Human K(ATP) channelopathies: diseases of metabolic homeostasis.Pflugers Arch. 2010 Jul;460(2):295-306. doi: 10.1007/s00424-009-0771-y. Epub 2009 Dec 24.
• [40] Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement.J Thromb Thrombolysis. 2018 Apr;45(3):463-465. doi: 10.1007/s11239-018-1636-z.
• [41] Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.Nat Genet. 2018 Sep;50(9):1234-1239. doi: 10.1038/s41588-018-0171-3. Epub 2018 Jul 30.
• [42] Metastable Atrial State Underlies the Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation.Circulation. 2020 Jan 28;141(4):301-312. doi: 10.1161/CIRCULATIONAHA.119.044268. Epub 2019 Nov 16.
• [43] Ivabradine for the Treatment of Cardiovascular Diseases.Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29.
• [44] Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation.Circulation. 2019 Apr 30;139(18):2157-2169. doi: 10.1161/CIRCULATIONAHA.118.036761.
• [45] PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention.Thromb Haemost. 2019 Mar;119(3):359-367. doi: 10.1055/s-0038-1676863. Epub 2019 Jan 3.
• [46] Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.Heart Rhythm. 2019 Sep;16(9):1374-1382. doi: 10.1016/j.hrthm.2019.04.008. Epub 2019 Apr 5.
• [47] Multi-ethnic genome-wide association study for atrial fibrillation.Nat Genet. 2018 Jun 11;50(9):1225-1233. doi: 10.1038/s41588-018-0133-9.
• [48] Regulation of the NRG1/ErbB4 Pathway in the Intrinsic Cardiac Nervous System Is a Potential Treatment for Atrial Fibrillation.Front Physiol. 2018 Aug 21;9:1082. doi: 10.3389/fphys.2018.01082. eCollection 2018.
• [49] Protective mechanism of SIRT1 on Hcy-induced atrial fibrosis mediated by TRPC3.J Cell Mol Med. 2020 Jan;24(1):488-510. doi: 10.1111/jcmm.14757. Epub 2019 Nov 4.
• [50] Modulation of miR-10a-mediated TGF-1/Smads signaling affects atrial fibrillation-induced cardiac fibrosis and cardiac fibroblast proliferation.Biosci Rep. 2019 Feb 8;39(2):BSR20181931. doi: 10.1042/BSR20181931. Print 2019 Feb 28.
• [51] Exome sequencing of a family with lone, autosomal dominant atrial flutter identifies a rare variation in ABCB4 significantly enriched in cases.BMC Genet. 2015 Feb 11;16:15. doi: 10.1186/s12863-015-0177-0.
• [52] Activin Receptor-Like Kinase 4 Haplodeficiency Mitigates Arrhythmogenic Atrial Remodeling and Vulnerability to Atrial Fibrillation in Cardiac Pathological Hypertrophy.J Am Heart Assoc. 2018 Aug 21;7(16):e008842. doi: 10.1161/JAHA.118.008842.
• [53] Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.Clin Appl Thromb Hemost. 2018 May;24(4):647-654. doi: 10.1177/1076029617711803. Epub 2017 Jun 15.
• [54] Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study.J Am Heart Assoc. 2018 Nov 20;7(22):e009509. doi: 10.1161/JAHA.118.009509.
• [55] Prevention of atrial fibrillation by bucindolol is dependent on the beta?89 Arg/Gly adrenergic receptor polymorphism.JACC Heart Fail. 2013 Aug;1(4):338-344. doi: 10.1016/j.jchf.2013.04.002.
• [56] Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311.
• [57] Involvement of Apelin/APJ Axis in Thrombogenesis in Valve Heart Disease Patients with Atrial Fibrillation.Int Heart J. 2019 Jan 25;60(1):145-150. doi: 10.1536/ihj.18-166. Epub 2018 Dec 5.
• [58] Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy. Circulation. 2004 Dec 21;110(25):3753-9. doi: 10.1161/01.CIR.0000150333.87176.C7. Epub 2004 Dec 13.
• [59] Diagnostic value of electrocardiographic P-wave characteristics in atrial fibrillation recurrence and tachycardia-induced cardiomyopathy after catheter ablation.Heart Vessels. 2018 Nov;33(11):1381-1389. doi: 10.1007/s00380-018-1179-4. Epub 2018 Apr 30.
• [60] Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.Clin Cardiol. 2017 Nov;40(11):1013-1019. doi: 10.1002/clc.22759. Epub 2017 Aug 14.
• [61] Age-related regulation and region-specific distribution of ion channel subunits promoting atrial fibrillation in human left and right atria.Europace. 2019 Aug 1;21(8):1261-1269. doi: 10.1093/europace/euz135.
• [62] Evaluation of the C(2)HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study).Am J Cardiol. 2020 Jan 1;125(1):48-54. doi: 10.1016/j.amjcard.2019.09.034. Epub 2019 Oct 10.
• [63] Comparison of current German and European practice in cardiac resynchronization therapy: lessons from the ESC/EHRA/HFA CRT Survey II.Clin Res Cardiol. 2020 Jul;109(7):832-844. doi: 10.1007/s00392-019-01574-z. Epub 2019 Dec 6.
• [64] Calpain-Calcineurin-Nuclear Factor Signaling and the Development of Atrial Fibrillation in Patients with Valvular Heart Disease and Diabetes.J Diabetes Res. 2016;2016:4639654. doi: 10.1155/2016/4639654. Epub 2016 Mar 31.
• [65] Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016 Aug;144:1-5.
• [66] Relationship between the TaqI B polymorphism of the cholesterol ester transfer protein gene and atrial fibrillation in Han and Kazak populations.Genet Mol Res. 2014 Feb 14;13(4):9300-7. doi: 10.4238/2014.February.14.4.
• [67] Modulative effects of lncRNA TCONS_00202959 on autonomic neural function and myocardial functions in atrial fibrillation rat model.Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8891-8897. doi: 10.26355/eurrev_201812_16658.
• [68] Contribution of acquired factors to the pathogenesis of dilated cardiomyopathy. -The cause of dilated cardiomyopathy: genetic or acquired? (Acquired-Side)-.Circ J. 2011;75(7):1766-73; discussion 1773. doi: 10.1253/circj.cj-11-0373. Epub 2011 May 27.
• [69] Trans-right axillary aortic valve replacement: propensity-matched comparison with standard sternotomy approach.Interact Cardiovasc Thorac Surg. 2017 Oct 1;25(4):521-525. doi: 10.1093/icvts/ivx238.
• [70] High mean platelet volume to platelet count ratio as a predictor on poor outcomes after CABG.Gen Thorac Cardiovasc Surg. 2020 May;68(5):459-466. doi: 10.1007/s11748-019-01202-7. Epub 2019 Sep 12.
• [71] Expression and activity of ectopeptidases in fibrillating human atria.J Mol Cell Cardiol. 2001 Jun;33(6):1273-81. doi: 10.1006/jmcc.2001.1389.
• [72] Association of peak atrial longitudinal strain with atrial fibrillation recurrence in patients with chronic lung diseases following radiofrequency ablation.Intern Med J. 2018 Jul;48(7):851-859. doi: 10.1111/imj.13768.
• [73] A comprehensive meta-analysis on relationship between CYP11B2 rs1799998 polymorphism and atrial fibrillation.J Electrocardiol. 2019 Jan-Feb;52:101-105. doi: 10.1016/j.jelectrocard.2018.11.009. Epub 2018 Nov 10.
• [74] Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis.J Cardiol. 2019 Jun;73(6):515-521. doi: 10.1016/j.jjcc.2018.12.018. Epub 2019 Feb 13.
• [75] CYP2J2/EET reduces vulnerability to atrial fibrillation in chronic pressure overload mice.J Cell Mol Med. 2020 Jan;24(1):862-874. doi: 10.1111/jcmm.14796. Epub 2019 Nov 20.
• [76] Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.Cardiovasc Drugs Ther. 2019 Oct;33(5):615-623. doi: 10.1007/s10557-019-06907-8.
• [77] Regulation of the TRPC1 channel by endothelin-1 in human atrial myocytes.Heart Rhythm. 2019 Oct;16(10):1575-1583. doi: 10.1016/j.hrthm.2019.04.003. Epub 2019 Apr 4.
• [78] A985G polymorphism of the endothelin-2 gene and atrial fibrillation in patients with hypertrophic cardiomyopathy.Circ J. 2007 Dec;71(12):1932-6. doi: 10.1253/circj.71.1932.
• [79] Long-range regulatory interactions at the 4q25 atrial fibrillation risk locus involve PITX2c and ENPEP.BMC Biol. 2015 Apr 17;13:26. doi: 10.1186/s12915-015-0138-0.
• [80] Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation.Int J Cardiol. 2013 Oct 9;168(4):3647-51. doi: 10.1016/j.ijcard.2013.05.010. Epub 2013 May 25.
• [81] Elevated blood plasma levels of tissue factor-bearing extracellular vesicles in patients with atrial fibrillation.Thromb Res. 2019 Jan;173:141-150. doi: 10.1016/j.thromres.2018.11.026. Epub 2018 Dec 2.
• [82] Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk.Ann Med. 2008;40(7):553-9. doi: 10.1080/07853890802108412.
• [83] Decreased gene expression of fatty acid binding protein 3 in the atrium of patients with new onset of atrial fibrillation in cardiac perioperative phase.J Cardiol. 2018 Jan;71(1):65-70. doi: 10.1016/j.jjcc.2017.07.003. Epub 2017 Aug 12.
• [84] Pleiotropic Meta-Analyses of Longitudinal Studies Discover Novel Genetic Variants Associated with Age-Related Diseases.Front Genet. 2016 Oct 13;7:179. doi: 10.3389/fgene.2016.00179. eCollection 2016.
• [85] Genome-wide Study of Atrial Fibrillation Identifies Seven Risk Loci and Highlights Biological Pathways and Regulatory Elements Involved in Cardiac Development.Am J Hum Genet. 2018 Jan 4;102(1):103-115. doi: 10.1016/j.ajhg.2017.12.003. Epub 2017 Dec 28.
• [86] Familial atrial fibrillation is a genetically heterogeneous disorder.J Am Coll Cardiol. 2003 Jun 18;41(12):2185-92. doi: 10.1016/s0735-1097(03)00465-0.
• [87] Atrial fibrillation and electrophysiology in transgenic mice with cardiac-restricted overexpression of FKBP12.Am J Physiol Heart Circ Physiol. 2019 Feb 1;316(2):H371-H379. doi: 10.1152/ajpheart.00486.2018. Epub 2018 Nov 30.
• [88] Presence and function of stress granules in atrial fibrillation.PLoS One. 2019 Apr 3;14(4):e0213769. doi: 10.1371/journal.pone.0213769. eCollection 2019.
• [89] Expression of tyrosine hydroxylase and growth-associated protein 43 in aging atrial fibrillation patients of Xinjiang Uygur and Han nationality.Genet Mol Res. 2013 Oct 30;12(4):5257-66. doi: 10.4238/2013.October.30.10.
• [90] Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.Clin Res Cardiol. 2020 Apr;109(4):426-434. doi: 10.1007/s00392-019-01522-x. Epub 2019 Jul 6.
• [91] Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang.Lipids Health Dis. 2013 Oct 23;12:149. doi: 10.1186/1476-511X-12-149.
• [92] Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease.Int J Mol Sci. 2018 Jan 19;19(1):295. doi: 10.3390/ijms19010295.
• [93] Relationship between two arrhythmias: sinus node dysfunction and atrial fibrillation.Arch Med Res. 2014 May;45(4):351-5. doi: 10.1016/j.arcmed.2014.04.005. Epub 2014 May 11.
• [94] Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.
• [95] Identification of microRNA-mRNA dysregulations in paroxysmal atrial fibrillation.Int J Cardiol. 2015 Apr 1;184:190-197. doi: 10.1016/j.ijcard.2015.01.075. Epub 2015 Jan 28.
• [96] GRK5 Polymorphisms and Postoperative Atrial Fibrillation following Coronary Artery Bypass Graft Surgery.Sci Rep. 2015 Aug 3;5:12768. doi: 10.1038/srep12768.
• [97] Identification of six new genetic loci associated with atrial fibrillation in the Japanese population.Nat Genet. 2017 Jun;49(6):953-958. doi: 10.1038/ng.3842. Epub 2017 Apr 17.
• [98] Remodeling of ion channel expression in patients with chronic atrial fibrillation and mitral valvular heart disease.Korean J Intern Med. 2010 Dec;25(4):377-85. doi: 10.3904/kjim.2010.25.4.377. Epub 2010 Nov 27.
• [99] Converse role of class I and class IIa HDACs in the progression of atrial fibrillation.J Mol Cell Cardiol. 2018 Dec;125:39-49. doi: 10.1016/j.yjmcc.2018.09.010. Epub 2018 Oct 12.
• [100] Ser96Ala genetic variant of the human histidine-rich calcium-binding protein is a genetic predictor of recurrence after catheter ablation in patients with paroxysmal atrial fibrillation.PLoS One. 2019 Mar 6;14(3):e0213208. doi: 10.1371/journal.pone.0213208. eCollection 2019.
• [101] Relationship of PCSK9 and UrinaryThromboxane Excretion toCardiovascular Events in PatientsWithAtrial Fibrillation.J Am Coll Cardiol. 2017 Sep 19;70(12):1455-1462. doi: 10.1016/j.jacc.2017.07.743.
• [102] Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery - a sub-analysis of the RIPHeart-Study.BMC Cardiovasc Disord. 2019 Jan 24;19(1):26. doi: 10.1186/s12872-019-1002-x.
• [103] Quantitative mRNA analysis of serotonin 5-HT4 receptor isoforms, calcium handling proteins and ion channels in human atrial fibrillation.Biochem Biophys Res Commun. 2007 May 25;357(1):218-24. doi: 10.1016/j.bbrc.2007.03.124. Epub 2007 Mar 28.
• [104] Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).Am Heart J. 2019 May;211:45-53. doi: 10.1016/j.ahj.2018.12.010. Epub 2018 Dec 21.
• [105] Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA(2)DS(2)-VASc Scores: Findings From the ORBIT-AF I and II Registries.J Am Heart Assoc. 2018 Aug 21;7(16):e008764. doi: 10.1161/JAHA.118.008764.
• [106] Relation of IGF-1 and IGFBP-3 with prevalent and incident atrial fibrillation in a population-based study.Heart Rhythm. 2019 Sep;16(9):1314-1319. doi: 10.1016/j.hrthm.2019.03.017. Epub 2019 Mar 22.
• [107] SNX17 (Sorting Nexin 17) Mediates Atrial Fibrillation Onset Through Endocytic Trafficking of the Kv1.5 (Potassium Voltage-Gated Channel Subfamily A Member 5) Channel.Circ Arrhythm Electrophysiol. 2019 Apr;12(4):e007097. doi: 10.1161/CIRCEP.118.007097.
• [108] The single nucleotide polymorphisms of I(Ks) potassium channel genes and their association with atrial fibrillation in a Chinese population.Cardiology. 2007;108(2):97-103. doi: 10.1159/000095943. Epub 2006 Sep 29.
• [109] Atrial Fibrillation in Long QT Syndrome by Genotype.Circ Arrhythm Electrophysiol. 2019 Oct;12(10):e007213. doi: 10.1161/CIRCEP.119.007213. Epub 2019 Oct 15.
• [110] Genetic susceptibility for ischemic infarction and arteriolosclerosis based on neuropathologic evaluations.Cerebrovasc Dis. 2013;36(3):181-188. doi: 10.1159/000352054. Epub 2013 Oct 12.
• [111] The research of ion channel-related gene polymorphisms with atrial fibrillation in the Chinese Han population.Mol Genet Genomic Med. 2019 Aug;7(8):e835. doi: 10.1002/mgg3.835. Epub 2019 Jul 4.
• [112] Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.Cell Physiol Biochem. 2019;52(5):1223-1235. doi: 10.33594/000000083.
• [113] pH-dependent inhibition of KP3.1 prolongs atrial refractoriness in whole hearts.Pflugers Arch. 2016 Apr;468(4):643-54. doi: 10.1007/s00424-015-1779-0. Epub 2016 Jan 5.
• [114] The membrane protein KCNQ1 potassium ion channel: Functional diversity and current structural insights.Biochim Biophys Acta Biomembr. 2020 May 1;1862(5):183148. doi: 10.1016/j.bbamem.2019.183148. Epub 2019 Dec 9.
• [115] Common variants in KCNN3 are associated with lone atrial fibrillation.Nat Genet. 2010 Mar;42(3):240-4. doi: 10.1038/ng.537. Epub 2010 Feb 21.
• [116] Atrial fibrillation is associated with alterations in HDL function, metabolism, and particle number.Basic Res Cardiol. 2019 May 8;114(4):27. doi: 10.1007/s00395-019-0735-0.
• [117] LIM kinase 1 acts as a profibrotic mediator in permanent atrial fibrillation patients with valvular heart disease.J Biosci. 2019 Mar;44(1):16.
• [118] Cardiac overexpression of perilipin 2 induces atrial steatosis, connexin 43 remodeling, and atrial fibrillation in aged mice.Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E1193-E1204. doi: 10.1152/ajpendo.00227.2019. Epub 2019 Oct 29.
• [119] Risk factors of thromboembolism in nonvalvular atrial fibrillation patients with low CHA2DS2-VASc score.Medicine (Baltimore). 2019 Feb;98(8):e14549. doi: 10.1097/MD.0000000000014549.
• [120] Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery.Am Heart J. 2015 Sep;170(3):580-90.e28. doi: 10.1016/j.ahj.2015.06.009. Epub 2015 Jun 17.
• [121] Circulating Mesencephalic Astrocyte-Derived Neurotrophic Factor Negatively Correlates With Atrial Apoptosis in Human Chronic Atrial Fibrillation.J Cardiovasc Pharmacol. 2020 Feb;75(2):141-147. doi: 10.1097/FJC.0000000000000781.
• [122] Role of Stress Kinase JNK in Binge Alcohol-Evoked Atrial Arrhythmia.J Am Coll Cardiol. 2018 Apr 3;71(13):1459-1470. doi: 10.1016/j.jacc.2018.01.060.
• [123] Refinement of detecting atrial fibrillation in stroke patients: results from the TRACK-AF Study.Eur J Neurol. 2018 Apr;25(4):631-636. doi: 10.1111/ene.13538. Epub 2018 Feb 13.
• [124] Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.Clin Res Cardiol. 2018 Sep;107(9):788-798. doi: 10.1007/s00392-018-1246-y. Epub 2018 Apr 11.
• [125] Role of Endothelial Nitric Oxide Synthase Polymorphisms in Atrial Fibrillation: A PRISMA-Compliant Meta-Analysis.Med Sci Monit. 2019 Apr 12;25:2687-2694. doi: 10.12659/MSM.913528.
• [126] NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.J Am Heart Assoc. 2019 Apr 2;8(7):e010868. doi: 10.1161/JAHA.118.010868.
• [127] Biomarkers in Atrial Fibrillation and Heart Failure.Curr Med Chem. 2019;26(5):873-887. doi: 10.2174/0929867324666170830100424.
• [128] DNA methylation dysregulations in valvular atrial fibrillation.Clin Cardiol. 2017 Sep;40(9):686-691. doi: 10.1002/clc.22715. Epub 2017 Aug 28.
• [129] Loss of Protein Phosphatase 1 Regulatory Subunit PPP1R3A Promotes Atrial Fibrillation.Circulation. 2019 Aug 20;140(8):681-693. doi: 10.1161/CIRCULATIONAHA.119.039642. Epub 2019 Jun 12.
• [130] Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial.Am J Cardiovasc Drugs. 2020 Feb;20(1):73-80. doi: 10.1007/s40256-019-00353-5.
• [131] Anticoagulation after catheter ablation of atrial fibrillation: An unnecessary evil? A systematic review and meta-analysis.J Cardiovasc Electrophysiol. 2019 Apr;30(4):468-478. doi: 10.1111/jce.13822. Epub 2019 Jan 7.
• [132] Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.Europace. 2020 Jan 1;22(1):33-46. doi: 10.1093/europace/euz259.
• [133] Association of prolidase activity, oxidative parameters, and presence of atrial fibrillation in patients with mitral stenosis.Arch Med Res. 2008 Jul;39(5):519-24. doi: 10.1016/j.arcmed.2008.03.002. Epub 2008 Apr 28.
• [134] Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation.Circ J. 2007 Feb;71(2):214-9. doi: 10.1253/circj.71.214.
• [135] Association of Healthcare Plan with atrial fibrillation prescription patterns.Clin Cardiol. 2018 Sep;41(9):1136-1143. doi: 10.1002/clc.23042. Epub 2018 Sep 22.
• [136] Novel Role for the Immunoproteasome Subunit PSMB10 in Angiotensin II-Induced Atrial Fibrillation in Mice.Hypertension. 2018 May;71(5):866-876. doi: 10.1161/HYPERTENSIONAHA.117.10390. Epub 2018 Mar 5.
• [137] Immunoproteasome Subunit 5i Promotes Ang II (Angiotensin II)-Induced Atrial Fibrillation by Targeting ATRAP (Ang II Type I Receptor-Associated Protein) Degradation in Mice.Hypertension. 2019 Jan;73(1):92-101. doi: 10.1161/HYPERTENSIONAHA.118.11813.
• [138] Exchange-protein activated by cAMP (EPAC) regulates L-type calcium channel in atrial fibrillation of heart failure model.Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2200-2207. doi: 10.26355/eurrev_201903_17267.
• [139] Essential role of the m2R-RGS6-IKACh pathway in controlling intrinsic heart rate variability.PLoS One. 2013 Oct 29;8(10):e76973. doi: 10.1371/journal.pone.0076973. eCollection 2013.
• [140] Postablation cerebral embolisms in balloon-based atrial fibrillation ablation with periprocedural direct oral anticoagulants: A comparison between cryoballoon and HotBalloon ablation.J Cardiovasc Electrophysiol. 2019 Jan;30(1):39-46. doi: 10.1111/jce.13762. Epub 2018 Oct 29.
• [141] "Pill-in-the-Pocket" Treatment of Propafenone Unmasks ECG Brugada Pattern in an Atrial Fibrillation Patient With a Common SCN5A R1193Q Polymorphism.Front Physiol. 2019 Mar 29;10:353. doi: 10.3389/fphys.2019.00353. eCollection 2019.
• [142] Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation.J Thromb Thrombolysis. 2017 Jan;43(1):18-23. doi: 10.1007/s11239-016-1427-3.
• [143] Chronic inhibition of the sigma-1 receptor exacerbates atrial fibrillation susceptibility in rats by promoting atrial remodeling.Life Sci. 2019 Oct 15;235:116837. doi: 10.1016/j.lfs.2019.116837. Epub 2019 Sep 4.
• [144] Myocardial perfusion during atrial fibrillation in patients with non-ischaemic systolic heart failure: a cross-sectional study using Rubidium-82 positron emission tomography/computed tomography.Eur Heart J Cardiovasc Imaging. 2019 Feb 1;20(2):233-240. doi: 10.1093/ehjci/jey089.
• [145] AT1 mutations and risk of atrial fibrillation based on genotypes from 71,000 individuals from the general population.Br J Clin Pharmacol. 2013 Jul;76(1):114-24. doi: 10.1111/bcp.12050.
• [146] Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.Thromb Haemost. 2018 Feb;118(2):229-250. doi: 10.1160/TH17-07-0492. Epub 2018 Jan 29.
• [147] Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.Diabetes Obes Metab. 2018 Feb;20(2):344-351. doi: 10.1111/dom.13077. Epub 2017 Sep 8.
• [148] ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population.Pharmacology. 2017;99(5-6):250-258. doi: 10.1159/000457906. Epub 2017 Feb 17.
• [149] FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways.J Cell Physiol. 2019 Nov;234(11):19502-19510. doi: 10.1002/jcp.28548. Epub 2019 Apr 5.
• [150] Role of Sprouty1 (Spry1) in the pathogenesis of atrial fibrosis.Pathol Res Pract. 2018 Feb;214(2):308-313. doi: 10.1016/j.prp.2017.04.021. Epub 2017 Apr 28.
• [151] Trends and Outcome of Catheter Ablation of Atrial Fibrillation Over 9 Years- Focus on Empirical Extra-Pulmonary Vein Ablation.Circ J. 2019 Jan 25;83(2):304-312. doi: 10.1253/circj.CJ-18-0928. Epub 2019 Jan 9.
• [152] Neurokinin-3 receptor activation selectively prolongs atrial refractoriness by inhibition of a background K(+) channel.Nat Commun. 2018 Oct 19;9(1):4357. doi: 10.1038/s41467-018-06530-5.
• [153] Combined metabolic, phenomic and genomic data to prioritize atrial fibrillation-related metabolites.Exp Ther Med. 2019 May;17(5):3929-3934. doi: 10.3892/etm.2019.7443. Epub 2019 Mar 26.
• [154] Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria.Circulation. 2003 Nov 18;108(20):2450-2. doi: 10.1161/01.CIR.0000102969.09658.F2. Epub 2003 Nov 10.
• [155] TRIF promotes angiotensin II-induced cross-talk between fibroblasts and macrophages in atrial fibrosis.Biochem Biophys Res Commun. 2015 Aug 14;464(1):100-5. doi: 10.1016/j.bbrc.2015.05.131. Epub 2015 Jun 5.
• [156] Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis.Exp Mol Pathol. 2015 Jun;98(3):486-90. doi: 10.1016/j.yexmp.2015.03.025. Epub 2015 Mar 18.
• [157] Modulation of Human Cardiac TRPM7 Current by Extracellular Acidic pH Depends upon Extracellular Concentrations of Divalent Cations.PLoS One. 2017 Jan 27;12(1):e0170923. doi: 10.1371/journal.pone.0170923. eCollection 2017.
• [158] SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation.Singapore Med J. 2020 Dec;61(12):641-646. doi: 10.11622/smedj.2019143. Epub 2019 Nov 4.
• [159] Improvement in Sleep-Disordered Breathing Indices Downloaded From a Positive Airway Pressure Machine Following Conversion of Atrial Fibrillation to Sinus Rhythm.J Clin Sleep Med. 2018 Nov 15;14(11):1953-1957. doi: 10.5664/jcsm.7502.
• [160] Inhibition of UCHL1 by LDN-57444 attenuates Ang II-Induced atrial fibrillation in mice.Hypertens Res. 2020 Mar;43(3):168-177. doi: 10.1038/s41440-019-0354-z. Epub 2019 Nov 7.
• [161] The differentiation of beige adipocyte in pericardial and epicardial adipose tissues induces atrial fibrillation development.Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4398-4405.
• [162] Role of UTS2 gene in the genetic susceptibility to atrial fibrillation in the Chinese population.Postgrad Med J. 2016 Apr;92(1086):201-7. doi: 10.1136/postgradmedj-2015-133699. Epub 2016 Jan 25.
• [163] Genetic variant in the promoter region of microRNA?37 reduces the warfarin maintenance dose in patients with atrial fibrillation.Mol Med Rep. 2019 Jun;19(6):5361-5367. doi: 10.3892/mmr.2019.10205. Epub 2019 Apr 30.
• [164] Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation.Can J Cardiol. 2020 Jan;36(1):119-126. doi: 10.1016/j.cjca.2019.08.001. Epub 2019 Aug 8.
• [165] MicroRNA-21 via Dysregulation of WW Domain-Containing Protein 1 Regulate Atrial Fibrosis in Atrial Fibrillation.Heart Lung Circ. 2018 Jan;27(1):104-113. doi: 10.1016/j.hlc.2016.01.022. Epub 2017 Mar 12.
• [166] Atrial fibrillation observed on surface ECG can be atrial flutter or atrial tachycardia.J Electrocardiol. 2018 Nov-Dec;51(6S):S67-S71. doi: 10.1016/j.jelectrocard.2018.07.010. Epub 2018 Jul 17.
• [167] Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?.Heart Fail Rev. 2020 Mar;25(2):367-380. doi: 10.1007/s10741-019-09837-7.
• [168] A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.Am Heart J. 2018 May;199:51-58. doi: 10.1016/j.ahj.2017.12.001. Epub 2017 Dec 6.
• [169] NPR-C (Natriuretic Peptide Receptor-C) Modulates the Progression of Angiotensin II-Mediated Atrial Fibrillation and Atrial Remodeling in Mice.Circ Arrhythm Electrophysiol. 2019 Jan;12(1):e006863. doi: 10.1161/CIRCEP.118.006863.
• [170] Liraglutide suppresses atrial electrophysiological changes.Heart Vessels. 2019 Aug;34(8):1389-1393. doi: 10.1007/s00380-018-01327-4. Epub 2019 Feb 14.
• [171] Assessment of Thrombotic Risk in Atrial Fibrillation with Ultrasound Molecular Imaging of P-Selectin.Thromb Haemost. 2018 Feb;118(2):388-400. doi: 10.1160/TH17-02-0103. Epub 2018 Jan 29.
• [172] Management of atrial fibrillation: easy as ABC.Minerva Med. 2019 Feb;110(1):27-34. doi: 10.23736/S0026-4806.18.05824-X. Epub 2018 Oct 11.
• [173] Whole-exome sequencing in familial atrial fibrillation.Eur Heart J. 2014 Sep 21;35(36):2477-83. doi: 10.1093/eurheartj/ehu156. Epub 2014 Apr 11.
• [174] TREK-1 (K(2P)2.1) K(+) channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control.Basic Res Cardiol. 2017 Jan;112(1):8. doi: 10.1007/s00395-016-0597-7. Epub 2016 Dec 22.
• [175] Identification of TNFSF13, SPATC1L, SLC22A25 and SALL4 as novel susceptibility loci for atrial fibrillation by an exomewide association study.Mol Med Rep. 2017 Nov;16(5):5823-5832. doi: 10.3892/mmr.2017.7334. Epub 2017 Aug 23.
• [176] Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation.J Cardiovasc Electrophysiol. 1999 Apr;10(4):552-60. doi: 10.1111/j.1540-8167.1999.tb00712.x.
• [177] Whole Blood Gene Expression Differentiates between Atrial Fibrillation and Sinus Rhythm after Cardioversion.PLoS One. 2016 Jun 22;11(6):e0157550. doi: 10.1371/journal.pone.0157550. eCollection 2016.
• [178] Gene-gene Interaction Analyses for Atrial Fibrillation.Sci Rep. 2016 Nov 8;6:35371. doi: 10.1038/srep35371.
• [179] The involvement of ZnT-1, a new modulator of cardiac L-type calcium channels, in [corrected] atrial tachycardia remodeling. [corrected].Ann N Y Acad Sci. 2010 Feb;1188:87-95. doi: 10.1111/j.1749-6632.2009.05087.x.
• [180] Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11.
• [181] Comparing radiofrequency and cryoballoon technology for the ablation of atrial fibrillation.Curr Opin Cardiol. 2019 Jan;34(1):1-5. doi: 10.1097/HCO.0000000000000578.
• [182] The rs2108622 polymorphism is related to the early risk of ischemic stroke in non-valvular atrial fibrillation subjects under oral anticoagulation.Pharmacogenomics J. 2018 Sep;18(5):652-656. doi: 10.1038/s41397-017-0007-z. Epub 2017 Dec 22.
• [183] Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation.Circulation. 2013 Oct 15;128(16):1748-57. doi: 10.1161/CIRCULATIONAHA.113.003313. Epub 2013 Sep 12.
• [184] Whole Exome Sequencing in Atrial Fibrillation.PLoS Genet. 2016 Sep 2;12(9):e1006284. doi: 10.1371/journal.pgen.1006284. eCollection 2016 Sep.
• [185] Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches.Curr Med Chem. 2019;26(5):765-779. doi: 10.2174/0929867324666170718130408.
• [186] Gain-of-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation.Biomark Med. 2014;8(4):557-70. doi: 10.2217/bmm.13.137.
• [187] Deletion in mice of X-linked, Brugada syndrome- and atrial fibrillation-associated Kcne5 augments ventricular K(V) currents and predisposes to ventricular arrhythmia.FASEB J. 2019 Feb;33(2):2537-2552. doi: 10.1096/fj.201800502R. Epub 2018 Oct 5.
• [188] Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.J Cardiovasc Electrophysiol. 2016 Oct;27(10):1214-1219. doi: 10.1111/jce.13029. Epub 2016 Jul 13.
• [189] PITX2 and NEURL1 SNP polymorphisms in Hungarian atrial fibrillation patients determined by quantitative real-time PCR and melting curve analysis.J Biotechnol. 2019 Jun 20;299:44-49. doi: 10.1016/j.jbiotec.2019.04.022. Epub 2019 Apr 27.
• [190] Patterns and Intensities of Near-Infrared and Short-Wavelength Fundus Autofluorescence in Choroideremia Probands and Carriers.Invest Ophthalmol Vis Sci. 2019 Sep 3;60(12):3752-3761. doi: 10.1167/iovs.19-27366.
• [191] Early differentiation of long-standing persistent atrial fibrillation using the characteristics of fibrillatory waves in surface ECG multi-leads.Sci Rep. 2019 Feb 26;9(1):2746. doi: 10.1038/s41598-019-38928-6.
• [192] Significant association of rare variant p.Gly8Ser in cardiac sodium channel 4-subunit SCN4B with atrial fibrillation.Ann Hum Genet. 2019 Jul;83(4):239-248. doi: 10.1111/ahg.12305. Epub 2019 Mar 1.
• [193] Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum Ca2+ uptake in human atrial fibrillation.Biochem Biophys Res Commun. 2011 Jun 24;410(1):97-101. doi: 10.1016/j.bbrc.2011.05.113. Epub 2011 May 25.
• [194] Clinical Implications of Preoperative Nonvalvular Atrial Fibrillation with Respect to Postoperative Cardiovascular Outcomes in Patients Undergoing Non-Cardiac Surgery.Korean Circ J. 2020 Feb;50(2):148-159. doi: 10.4070/kcj.2019.0219. Epub 2019 Nov 19.
• [195] Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank.Circ Res. 2020 Jan 17;126(2):200-209. doi: 10.1161/CIRCRESAHA.119.315686. Epub 2019 Nov 6.
• [196] Genomic Variants in NEURL, GJA1 and CUX2 Significantly Increase Genetic Susceptibility to Atrial Fibrillation.Sci Rep. 2018 Feb 19;8(1):3297. doi: 10.1038/s41598-018-21611-7.
• [197] Calcium-Mediated Oscillation in Membrane Potentials and Atrial-Triggered Activity in Atrial Cells of Casq2(R33Q/R33Q) Mutation Mice.Front Physiol. 2018 Nov 2;9:1447. doi: 10.3389/fphys.2018.01447. eCollection 2018.
• [198] [Effect of benazepril on atrial cytoskeleton remodeling in the canine atrial fibrillation models].Zhonghua Yi Xue Za Zhi. 2009 Oct 20;89(38):2718-21.
• [199] Paroxysmal Atrial Fibrillation in the Course of Acute Pulmonary Embolism: Clinical Significance and Impact on Prognosis.Biomed Res Int. 2017;2017:5049802. doi: 10.1155/2017/5049802. Epub 2017 Feb 9.
• [200] Disease modeling of a mutation in -actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.EMBO Mol Med. 2019 Dec;11(12):e11115. doi: 10.15252/emmm.201911115. Epub 2019 Nov 3.
• [201] Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria.Circulation. 2002 Feb 12;105(6):720-5. doi: 10.1161/hc0602.103639.
• [202] Lamin A mutation impairs interaction with nucleoporin NUP155 and disrupts nucleocytoplasmic transport in atrial fibrillation.Hum Mutat. 2019 Mar;40(3):310-325. doi: 10.1002/humu.23691. Epub 2018 Dec 8.
• [203] Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke.Sci Rep. 2016 Mar 17;6:23207. doi: 10.1038/srep23207.
• [204] Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation.Pacing Clin Electrophysiol. 2019 Jun;42(6):694-704. doi: 10.1111/pace.13669. Epub 2019 Apr 9.
• [205] Effectiveness of the Chest Strap Electrocardiogram to Detect Atrial Fibrillation.Am J Cardiol. 2019 May 15;123(10):1643-1648. doi: 10.1016/j.amjcard.2019.02.028. Epub 2019 Feb 23.
• [206] MicroRNA?4a mediates atrial fibrillation through regulation of AnkyrinB expression.Mol Med Rep. 2018 Jun;17(6):8457-8465. doi: 10.3892/mmr.2018.8873. Epub 2018 Apr 12.
• [207] Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation.Nat Genet. 2017 Jun;49(6):946-952. doi: 10.1038/ng.3843. Epub 2017 Apr 17.
• [208] Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip.Heart. 2017 Mar;103(5):377-382. doi: 10.1136/heartjnl-2016-309764. Epub 2016 Sep 8.
• [209] Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9.
• [210] Indexes of cerebral autoregulation do not reflect impairment in syncope: insights from head-up tilt test of vasovagal and autonomic failure subjects.Eur J Appl Physiol. 2017 Sep;117(9):1817-1831. doi: 10.1007/s00421-017-3674-1. Epub 2017 Jul 5.
• [211] Atrial fibrillation risk loci interact to modulate Ca2+-dependent atrial rhythm homeostasis.J Clin Invest. 2019 Nov 1;129(11):4937-4950. doi: 10.1172/JCI124231.
• [212] Long-term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization-activated cyclic nucleotide gated channel overexpression.J Cardiovasc Electrophysiol. 2019 Feb;30(2):242-252. doi: 10.1111/jce.13772. Epub 2018 Nov 5.
• [213] BET 1: Lenient or strict rate control for atrial fibrillation.Emerg Med J. 2018 Dec;35(12):765-768. doi: 10.1136/emermed-2018-208261.1.
• [214] Presence of rd8 mutation does not alter the ocular phenotype of late-onset retinal degeneration mouse model.Mol Vis. 2015 Mar 13;21:273-84. eCollection 2015.
• [215] CTRP9 Ameliorates Atrial Inflammation, Fibrosis, and Vulnerability to Atrial Fibrillation in Post-Myocardial Infarction Rats.J Am Heart Assoc. 2019 Nov 5;8(21):e013133. doi: 10.1161/JAHA.119.013133. Epub 2019 Oct 18.
• [216] Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.Circulation. 2018 Aug 28;138(9):874-885. doi: 10.1161/CIRCULATIONAHA.118.035090.
• [217] Prediction of electro-anatomical substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation.Sci Rep. 2018 Aug 23;8(1):12686. doi: 10.1038/s41598-018-31133-x.
• [218] Targeted sequencing in candidate genes for atrial fibrillation: the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing Study.Heart Rhythm. 2014 Mar;11(3):452-7. doi: 10.1016/j.hrthm.2013.11.012. Epub 2013 Nov 14.
• [219] Caveolae-Mediated Activation of Mechanosensitive Chloride Channels in Pulmonary Veins Triggers Atrial Arrhythmogenesis.J Am Heart Assoc. 2019 Oct 15;8(20):e012748. doi: 10.1161/JAHA.119.012748. Epub 2019 Oct 10.
• [220] Genome-wide DNA methylation analysis in permanent atrial fibrillation.Mol Med Rep. 2017 Oct;16(4):5505-5514. doi: 10.3892/mmr.2017.7221. Epub 2017 Aug 10.
• [221] Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.J Thromb Thrombolysis. 2019 Aug;48(2):240-249. doi: 10.1007/s11239-019-01838-5.
• [222] An X-linked channelopathy with cardiomegaly due to a CLIC2 mutation enhancing ryanodine receptor channel activity. Hum Mol Genet. 2012 Oct 15;21(20):4497-507. doi: 10.1093/hmg/dds292. Epub 2012 Jul 19.
• [223] Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes.BMC Med Genet. 2007 Sep 19;8 Suppl 1(Suppl 1):S5. doi: 10.1186/1471-2350-8-S1-S5.
• [224] Clinical Outcomes of Valvular versus Nonvalvular Atrial Fibrillation in Acute Anterior Circulation Occlusive Stroke Undergoing Endovascular Treatment.J Stroke Cerebrovasc Dis. 2019 Jan;28(1):31-37. doi: 10.1016/j.jstrokecerebrovasdis.2018.09.009. Epub 2018 Oct 2.
• [225] Prevalence and Incidence of Atrial Fibrillation in the General Population Based on National Health Insurance Special Health Checkups- TAMA MED Project-AF.Circ J. 2019 Feb 25;83(3):524-531. doi: 10.1253/circj.CJ-18-1038. Epub 2019 Jan 11.
• [226] Combination of Circulating Type I Collagen-Related Biomarkers Is AssociatedWith AtrialFibrillation.J Am Coll Cardiol. 2019 Apr 2;73(12):1398-1410. doi: 10.1016/j.jacc.2018.12.074.
• [227] Cardiac Sympathetic Denervation Suppresses Atrial Fibrillation and Blood Pressure in a Chronic Intermittent Hypoxia Rat Model of Obstructive Sleep Apnea.J Am Heart Assoc. 2019 Feb 19;8(4):e010254. doi: 10.1161/JAHA.118.010254.
• [228] Central Sleep Apnea with Cheyne-Stokes Breathing in Heart Failure - From Research to Clinical Practice and Beyond.Adv Exp Med Biol. 2018;1067:327-351. doi: 10.1007/5584_2018_146.
• [229] Safety and efficacy of mechanical thrombectomy in acute ischemic stroke of anticoagulated patients.J Neurointerv Surg. 2018 Dec;10(12):e29. doi: 10.1136/neurintsurg-2017-013714. Epub 2018 Mar 30.
• [230] Interaction of MIF Family Proteins in Myocardial Ischemia/Reperfusion Damage and Their Influence on Clinical Outcome of Cardiac Surgery Patients.Antioxid Redox Signal. 2015 Oct 10;23(11):865-79. doi: 10.1089/ars.2014.6243. Epub 2015 Aug 11.
• [231] Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.J Pharm Pharm Sci. 2017;20:8-14. doi: 10.18433/J30W4F.
• [232] Neural substrate of posterior left atrium: A novel modulation for inducibility and remodeling of atrial fibrillation in canine.PLoS One. 2017 May 5;12(5):e0176626. doi: 10.1371/journal.pone.0176626. eCollection 2017.
• [233] A Potential Role of Esophageal Cancer Related Gene-4 for Atrial Fibrillation.Sci Rep. 2017 Jun 2;7(1):2717. doi: 10.1038/s41598-017-02902-x.
• [234] The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG()), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT).Scand J Clin Lab Invest. 2018 Feb-Apr;78(1-2):25-30. doi: 10.1080/00365513.2017.1408138. Epub 2018 Jan 5.
• [235] X-linked nonsyndromic sinus node dysfunction and atrial fibrillation caused by emerin mutation.J Cardiovasc Electrophysiol. 2008 May;19(5):510-5. doi: 10.1111/j.1540-8167.2007.01081.x. Epub 2008 Feb 4.
• [236] Association of serum adropin with the presence of atrial fibrillation and atrial remodeling.J Clin Lab Anal. 2019 Feb;33(2):e22672. doi: 10.1002/jcla.22672. Epub 2018 Sep 21.
• [237] The Transcription Factor ETV1 Induces Atrial Remodeling and Arrhythmia.Circ Res. 2018 Aug 17;123(5):550-563. doi: 10.1161/CIRCRESAHA.118.313036.
• [238] Genetic variants associated with risk of atrial fibrillation regulate expression of PITX2, CAV1, MYOZ1, C9orf3 and FANCC.J Mol Cell Cardiol. 2015 Aug;85:207-14. doi: 10.1016/j.yjmcc.2015.06.005. Epub 2015 Jun 11.
• [239] Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial.Europace. 2019 May 1;21(5):746-753. doi: 10.1093/europace/euy325.
• [240] The -fibrinogen gene 455G/A polymorphism associated with cardioembolic stroke in atrial fibrillation with low CHA(2)DS(2)-VaSc score.Sci Rep. 2017 Dec 13;7(1):17517. doi: 10.1038/s41598-017-17537-1.
• [241] STAR mapping method to identify driving sites in persistent atrial fibrillation: Application through sequential mapping.J Cardiovasc Electrophysiol. 2019 Dec;30(12):2694-2703. doi: 10.1111/jce.14201. Epub 2019 Oct 3.
• [242] Predictors for Intracranial Hemorrhage Following Intravenous Thrombolysis in Posterior Circulation Stroke.Transl Stroke Res. 2018 Dec;9(6):582-588. doi: 10.1007/s12975-018-0608-0. Epub 2018 Jan 15.
• [243] Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: ARetrospective Cohort Study.J Am Heart Assoc. 2018 Aug 7;7(15):e009263. doi: 10.1161/JAHA.118.009263.
• [244] A novel GATA5 loss-of-function mutation underlies lone atrial fibrillation.Int J Mol Med. 2013 Jan;31(1):43-50. doi: 10.3892/ijmm.2012.1189. Epub 2012 Nov 20.
• [245] Gain-of-function mutations in GATA6 lead to atrial fibrillation.Heart Rhythm. 2017 Feb;14(2):284-291. doi: 10.1016/j.hrthm.2016.10.014. Epub 2016 Oct 15.
• [246] Genome-wide profiling reveals atrial fibrillation-related circular RNAs in atrial appendages.Gene. 2020 Feb 20;728:144286. doi: 10.1016/j.gene.2019.144286. Epub 2019 Dec 12.
• [247] Direct bilirubin level is an independent risk factor for atrial fibrillation in thyrotoxic patients receiving radioactive iodine therapy.Nucl Med Commun. 2019 Dec;40(12):1289-1294. doi: 10.1097/MNM.0000000000001107.
• [248] C825T polymorphism of the G-protein beta3 subunit gene and atrial fibrillation: association of the TT genotype with a reduced risk for atrial fibrillation.Am Heart J. 2004 Sep;148(3):545-50. doi: 10.1016/j.ahj.2004.03.024.
• [249] Functional consequences of genetic variation in sodium channel modifiers in early onset lone atrial fibrillation.Per Med. 2018 Mar;15(2):93-102. doi: 10.2217/pme-2017-0076. Epub 2018 Jan 31.
• [250] Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm.Dis Model Mech. 2013 Mar;6(2):332-41. doi: 10.1242/dmm.010488. Epub 2012 Dec 7.
• [251] Oral anticoagulant therapy in adults with congenital heart disease and atrial arrhythmias: Implementation of guidelines.Int J Cardiol. 2018 Apr 15;257:67-74. doi: 10.1016/j.ijcard.2017.12.038.
• [252] Brugada syndrome risk loci seem protective against atrial fibrillation.Eur J Hum Genet. 2014 Dec;22(12):1357-61. doi: 10.1038/ejhg.2014.46. Epub 2014 Mar 26.
• [253] Amino Acid-Based Metabolic Panel Provides Robust Prognostic Value Additive to B-Natriuretic Peptide and Traditional Risk Factors in Heart Failure.Dis Markers. 2018 Oct 10;2018:3784589. doi: 10.1155/2018/3784589. eCollection 2018.
• [254] RNA sequencing profiling reveals key mRNAs and long noncoding RNAs in atrial fibrillation.J Cell Biochem. 2020 Aug;121(8-9):3752-3763. doi: 10.1002/jcb.29504. Epub 2019 Nov 3.
• [255] Association of Met439Thr substitution in heat shock protein 70 gene with postoperative atrial fibrillation and serum HSP70 protein levels.Cardiology. 2008;110(1):45-52. doi: 10.1159/000109406. Epub 2007 Oct 10.
• [256] Rs12976445 Polymorphism Is Associated with Post-Ablation Recurrence of Atrial Fibrillation by Modulating the Expression of MicroRNA-125a and Interleukin-6R.Med Sci Monit. 2018 Sep 11;24:6349-6358. doi: 10.12659/MSM.908555.
• [257] Integrative analysis of transcriptome-wide association study data and mRNA expression profiles identified candidate genes and pathways associated with atrial fibrillation.Heart Vessels. 2019 Nov;34(11):1882-1888. doi: 10.1007/s00380-019-01418-w. Epub 2019 May 7.
• [258] Impact of intravenous thrombolysis on length of hospital stay in cases of acute ischemic stroke.Neuropsychiatr Dis Treat. 2018 Jan 9;14:259-264. doi: 10.2147/NDT.S151836. eCollection 2018.
• [259] GPIIb/IIIa expression changes in atrial fibrillation post radiofrequency ablation.Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6959-6964. doi: 10.26355/eurrev_201810_16166.
• [260] Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial.Circ Arrhythm Electrophysiol. 2019 Dec;12(12):e007731. doi: 10.1161/CIRCEP.119.007731. Epub 2019 Nov 25.
• [261] Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects.Int J Cardiol. 2018 Nov 15;271:219-227. doi: 10.1016/j.ijcard.2018.05.033. Epub 2018 May 24.
• [262] Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation.Eur Heart J. 2013 May;34(20):1517-25. doi: 10.1093/eurheartj/ehs442. Epub 2012 Dec 21.
• [263] The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease.Biochem Biophys Res Commun. 2019 Oct 29;519(1):141-147. doi: 10.1016/j.bbrc.2019.08.150. Epub 2019 Aug 31.
• [264] Deep sequencing of atrial fibrillation patients with mitral valve regurgitation shows no evidence of mosaicism but reveals novel rare germline variants.Heart Rhythm. 2017 Oct;14(10):1531-1538. doi: 10.1016/j.hrthm.2017.05.027. Epub 2017 May 24.
• [265] Genome-wide screening identifies a KCNIP1 copy number variant as a genetic predictor for atrial fibrillation.Nat Commun. 2016 Feb 2;7:10190. doi: 10.1038/ncomms10190.
• [266] The two-pore domain potassium channel, TWIK-1, has a role in the regulation of heart rate and atrial size.J Mol Cell Cardiol. 2016 Aug;97:24-35. doi: 10.1016/j.yjmcc.2016.04.006. Epub 2016 Apr 19.
• [267] Cardiac K(2P)13.1 (THIK-1) two-pore-domain K(+) channels: Pharmacological regulation and remodeling in atrial fibrillation.Prog Biophys Mol Biol. 2019 Jul;144:128-138. doi: 10.1016/j.pbiomolbio.2018.06.009. Epub 2018 Jul 6.
• [268] Identification and functional characterization of zebrafish K(2P)17.1 (TASK-4, TALK-2) two-pore-domain K(+) channels.Eur J Pharmacol. 2018 Jul 15;831:94-102. doi: 10.1016/j.ejphar.2018.05.007. Epub 2018 May 9.
• [269] TASK-1 current is inhibited by phosphorylation during human and canine chronic atrial fibrillation.Am J Physiol Heart Circ Physiol. 2015 Jan 15;308(2):H126-34. doi: 10.1152/ajpheart.00614.2014. Epub 2014 Nov 26.
• [270] Ectopy on a Single 12-Lead ECG, Incident Cardiac Myopathy, and Death in the Community.J Am Heart Assoc. 2017 Aug 3;6(8):e006028. doi: 10.1161/JAHA.117.006028.
• [271] Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age.J Am Heart Assoc. 2014 Apr 10;3(2):e000340. doi: 10.1161/JAHA.113.000340.
• [272] Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery.Circulation. 2019 Jan 22;139(4):489-501. doi: 10.1161/CIRCULATIONAHA.118.035774. Epub 2018 Nov 11.
• [273] The STOP-BANG questionnaire shows an insufficient specificity for detecting obstructive sleep apnea in patients with atrial fibrillation.J Sleep Res. 2018 Dec;27(6):e12702. doi: 10.1111/jsr.12702. Epub 2018 Apr 22.
• [274] Increased plasma microfibrillar-associated protein 4 is associated with atrial fibrillation and more advanced left atrial remodelling.Arch Med Sci. 2019 May;15(3):632-640. doi: 10.5114/aoms.2018.74953. Epub 2018 Apr 6.
• [275] MinK gene polymorphism in the pathogenesis of lone atrial fibrillation.Kardiol Pol. 2006 Nov;64(11):1205-11; discussion 1212-3.
• [276] Persistent left superior vena cava as an arrhythmogenic source in atrial fibrillation: results from a multicenter experience.J Interv Card Electrophysiol. 2019 Mar;54(2):93-100. doi: 10.1007/s10840-018-0444-x. Epub 2018 Sep 27.
• [277] Potential roles of circulating matrix metalloproteinase-28 (MMP-28) in patients with atrial fibrillation.Life Sci. 2018 Jul 1;204:15-19. doi: 10.1016/j.lfs.2018.04.053. Epub 2018 May 2.
• [278] Cardiac autonomic dynamics during sleep are lost in patients with TIA and stroke.J Sleep Res. 2020 Jun;29(3):e12878. doi: 10.1111/jsr.12878. Epub 2019 Jun 13.
• [279] Genetic polymorphisms confer risk of atrial fibrillation in patients with heart failure: a population-based study.Eur J Heart Fail. 2013 Mar;15(3):250-7. doi: 10.1093/eurjhf/hfs176. Epub 2012 Nov 6.
• [280] Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-1 levels in serum of patients with atrial fibrillation.BMC Cardiovasc Disord. 2014 Nov 25;14:167. doi: 10.1186/1471-2261-14-167.
• [281] Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial.Trials. 2018 Feb 20;19(1):117. doi: 10.1186/s13063-018-2487-9.
• [282] Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial.Rev Port Cardiol (Engl Ed). 2018 Dec;37(12):973-978. doi: 10.1016/j.repc.2018.01.013. Epub 2018 Dec 7.
• [283] NKX2-6 mutation predisposes to familial atrial fibrillation.Int J Mol Med. 2014 Dec;34(6):1581-90. doi: 10.3892/ijmm.2014.1971. Epub 2014 Oct 16.
• [284] Management of aortic valve replacement according to the gradient across symptomatic aortic valve stenosis and its prognostic impact.Echocardiography. 2019 Dec;36(12):2136-2144. doi: 10.1111/echo.14531. Epub 2019 Nov 8.
• [285] Cardioembolic Ischemic Stroke Gene Expression Fingerprint in Blood: a Systematic Review and Verification Analysis.Transl Stroke Res. 2020 Jun;11(3):326-336. doi: 10.1007/s12975-019-00730-x. Epub 2019 Sep 2.
• [286] Comparing severity scores in exacerbations of chronic obstructive pulmonary disease.Clin Respir J. 2018 Dec;12(12):2668-2675. doi: 10.1111/crj.12973.
• [287] Leukocyte TRP channel gene expressions inpatients with non-valvular atrial fibrillation.Sci Rep. 2017 Aug 24;7(1):9272. doi: 10.1038/s41598-017-10039-0.
• [288] A Missense Variant in PLEC Increases Riskof Atrial Fibrillation.J Am Coll Cardiol. 2017 Oct 24;70(17):2157-2168. doi: 10.1016/j.jacc.2017.09.005.
• [289] Analysis of Genes Involved in Persistent Atrial Fibrillation: Comparisons of 'Trigger' and 'Substrate' Differences.Cell Physiol Biochem. 2018;47(3):1299-1309. doi: 10.1159/000490225. Epub 2018 Jun 15.
• [290] Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy.Circulation. 2001 Dec 18;104(25):3030-3. doi: 10.1161/hc5001.102111.
• [291] Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.Patient Prefer Adherence. 2018 Jan 4;12:79-87. doi: 10.2147/PPA.S131158. eCollection 2018.
• [292] Identification of functional lncRNAs in atrial fibrillation by integrative analysis of the lncRNA-mRNA network based on competing endogenous RNAs hypothesis.J Cell Physiol. 2019 Jul;234(7):11620-11630. doi: 10.1002/jcp.27819. Epub 2018 Nov 27.
• [293] Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis.BMC Cardiovasc Disord. 2015 Sep 29;15:104. doi: 10.1186/s12872-015-0100-7.
• [294] Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation.Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1144-1152. doi: 10.2215/CJN.13811217. Epub 2018 Jul 12.
• [295] Proteomic profile of patients with atrial fibrillation undergoing cardiac surgery.Interact Cardiovasc Thorac Surg. 2019 Jan 1;28(1):94-101. doi: 10.1093/icvts/ivy210.
• [296] Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.Biochem Biophys Res Commun. 2017 Aug 26;490(3):643-649. doi: 10.1016/j.bbrc.2017.06.091. Epub 2017 Jun 17.
• [297] Rac1 GTPase regulates 11 hydroxysteroid dehydrogenase type 2 and fibrotic remodeling.J Biol Chem. 2017 May 5;292(18):7542-7553. doi: 10.1074/jbc.M116.764449. Epub 2017 Mar 20.
• [298] Mutations in GPR143/OA1 and ABCA4 Inform Interpretations of Short-Wavelength and Near-Infrared Fundus Autofluorescence.Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2459-2469. doi: 10.1167/iovs.18-24213.
• [299] Renin-angiotensin system-related gene polymorphisms are associated with risk of atrial fibrillation.Am Heart J. 2010 Sep;160(3):496-505. doi: 10.1016/j.ahj.2010.06.013.
• [300] Upregulation of sestrins protect atriums against oxidative damage and fibrosis in human and experimental atrial fibrillation.Sci Rep. 2017 Apr 11;7:46307. doi: 10.1038/srep46307.
• [301] Aplastic Anemia and Risk of Incident Atrial Fibrillation- A Nationwide Cohort Study.Circ J. 2018 Apr 25;82(5):1279-1285. doi: 10.1253/circj.CJ-17-0519. Epub 2018 Feb 16.
• [302] Proinflammatory gene expression in patients undergoing mitral valve surgery and maze ablation for atrial fibrillation.J Thorac Cardiovasc Surg. 2016 Jun;151(6):1673-1682.e5. doi: 10.1016/j.jtcvs.2015.12.003. Epub 2015 Dec 13.
• [303] A SHOX2 loss-of-function mutation underlying familial atrial fibrillation.Int J Med Sci. 2018 Oct 20;15(13):1564-1572. doi: 10.7150/ijms.27424. eCollection 2018.
• [304] Smart detection of atrial fibrillation?"Krivoshei L. Burkard T
• [305] Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.Eur Heart J. 2019 Dec 7;40(46):3757-3767. doi: 10.1093/eurheartj/ehz732.
• [306] A calcium transport mechanism for atrial fibrillation in Tbx5-mutant mice.Elife. 2019 Mar 21;8:e41814. doi: 10.7554/eLife.41814.
• [307] Integrated analysis of microRNA and mRNA expression profiles in the left atrium of patients with nonvalvular paroxysmal atrial fibrillation: Role of miR-146b-5p in atrial fibrosis.Heart Rhythm. 2015 May;12(5):1018-26. doi: 10.1016/j.hrthm.2015.01.026. Epub 2015 Jan 21.
• [308] Potential role of MG53 in the regulation of transforming-growth-factor-1-induced atrial fibrosis and vulnerability to atrial fibrillation.Exp Cell Res. 2018 Jan 15;362(2):436-443. doi: 10.1016/j.yexcr.2017.12.007. Epub 2017 Dec 9.
• [309] Unilateral Acute Renal Artery Embolism: An Index Case of Successful Mechanical Aspiration Thrombectomy With Use of Penumbra Indigo Aspiration System and a Review of the Literature.Vasc Endovascular Surg. 2018 Jul;52(5):391-394. doi: 10.1177/1538574418764052. Epub 2018 Mar 19.
• [310] Upregulation of miR-133b and miR-328 in Patients With Atrial Dilatation: Implications for Stretch-Induced Atrial Fibrillation.Front Physiol. 2019 Sep 10;10:1133. doi: 10.3389/fphys.2019.01133. eCollection 2019.
• [311] Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis.Europace. 2017 Mar 1;19(3):392-400. doi: 10.1093/europace/euw088.